UNSPSC 51401706: Benzoctamine hydrochloride

This classification denotes an anxiolytic with the molecular formula C18H19N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1C280S920Q, chemically known as 9,10-ethanoanthracene-9(10h)-methanamine, n-methyl-, hydrochloride but more generally known as benzoctamine hydrochloride, which bears US NIH Compound Identifier 66275. European Medicines Agency schedules Benzoctamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00723MIG.

Most nations, for tariff and trade purposes, schedule benzoctamine hydrochloride under HS 29214980 and SITC 51454. As of Q4 2014, BENZOCTAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Benzoctamine hydrochloride bears US NLM identifiers UMLS ID C0960020 and NCI Concept Code C83546. SMILES: CNCC12CCC(C3C1CCCC3)C4C2CCCC4.CL.

UNSPSC 51401706 Benzoctamine hydrochloride is a Commodity code that nominally covers a single pharmaceutical substance, but recent state and local solicitations show minimal direct procurement activity for benzoctamine itself. Instead, the code appears in contexts where state and local health agencies and cooperative purchasing alliances are soliciting broader pharmaceutical inventories—naloxone, generic multi-source drugs, and OTC products—often bundled with other therapeutics rather than benzoctamine as a line item. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope of work centers on pharmaceutical procurement, supply chain logistics, wholesale distribution relationships, and compliance with FDA, cGMP, and Drug Supply Chain Security Act (DSCSA) requirements.

Recent activity spans Florida, Texas, Minnesota, and Oregon through cooperative purchasing mechanisms. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: date appears inconsistent with posting date). The Texas HHS Commission released RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling early-stage procurement exploration rather than formal competitive bidding. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, establishing pricing agreements effective July 1, 2026 through authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson). Vendors under MMCAP must meet cGMP certification, DSCSA compliance, maintain relationships with at least two of three authorized wholesalers, and accept a 3 percent administrative fee. The code shows limited direct activity for benzoctamine; procurement under related pharmaceutical categories dominates the recent record.